title: Surfactant therapy prior to the interhospital transport of preterm infants.
abstract: The risk-to-benefit ratio of surfactant treatment of outborn preterm infants prior, as opposed to after, transportation to a perinatal center is not known. The objective of this study was to document current practice and to examine clinical outcomes in North America. In phase I (December, 1991 to January, 1992) questionnaires were distributed to 114 perinatal centers in the United States and Canada. The centers returned 98 surveys. Over half (50.5%) of the centers report giving surfactant rescue prior to infant transport, but only a minority (9.5%) of the centers report doing so for prophylaxis. In phase II (January, 1992 to December, 1992), clinical outcomes of surfactant-eligible babies requiring interhospital transport at a university hospital were evaluated to determine which infants ultimately received surfactant and when. The infants were compared between groups and did not differ significantly in gestational age, birthweight, sex type, number of multiple births, five-minute Apgar scores, or whether antenatal steroids were used. In phase II, the 66 consecutive, ventilator-dependent, outborn infants with average, and median, gestational age of 28 weeks were compared. The infants receiving surfactant prior to transport, when compared to the infants that got it after transport (9 hours later), did not do any better. There was 6% more survival without bronchopulmonary dysplasia in the group receiving surfactant after transport (65.2% versus 59.3%, p = 0.665). The infants receiving surfactant after transport were off the ventilator sooner (95% C.I. 6.0-28.7 versus 11.8-25.9 days) and discharged from the perinatal center earlier (95% C.I. 37.8-70.8 versus 47.9-69.0 days). Furthermore, arterial blood gases before and after transport reveals that there were no short-term advantages in administering surfactant prior to transport when compared to waiting for reevaluation at the perinatal center. These findings suggest that surfactant can be used safely prior to the interhospital transport of preterm infants, but this treatment does not seem to confer benefit over waiting for reevaluation, and possible surfactant treatment, at the tertiary perinatal center.
authors.affiliation: Franciscan Skemp Healthcare (Mayo Health System), La Crosse, Wisconsin, USA. d.costako@fsh.mayo.edu
authors.forename: D
authors.initials: D
authors.lastname: Costakos
authors.forename: D
authors.initials: D
authors.lastname: Allen
authors.forename: A
authors.initials: A
authors.lastname: Krauss
authors.forename: N
authors.initials: N
authors.lastname: Ruiz
authors.forename: K
authors.initials: K
authors.lastname: Fluhr
authors.forename: A
authors.initials: A
authors.lastname: Stouvenel
authors.forename: C
authors.initials: C
authors.lastname: Paxson
mesh_terms: D000280:Administration, Inhalation; D001784:Blood Gas Analysis; D001997:Bronchopulmonary Dysplasia / Q000097:blood / Q000401:mortality / Q000628:therapy*; D002170:Canada / Q000453:epidemiology; D005260:Female; D006801:Humans; D006819:Hyaline Membrane Disease / Q000097:blood / Q000401:mortality / Q000628:therapy*; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D010360:Patient Transfer; D018743:Perinatal Care / Q000379:methods*; D011663:Pulmonary Surfactants / Q000008:administration & dosage*; D012121:Respiration, Artificial / Q000379:methods; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D015996:Survival Rate; D014481:United States / Q000453:epidemiology
chemical_list: D011663:Pulmonary Surfactants